# GHIT Fund Advancing Portfolio

## DRUG DEVELOPMENT

### 1st PROJECT SCOPE
- **Target Validation**
  - [Phase 1](#) Clinical Development
    - Product Development Platform
    - Preclinical Development
    - Clinical Development

### 2nd PROJECT SCOPE
- **Phase 1** Clinical Development
  - [Product Development Platform](#)
  - [Hit Identification](#)
  - [Screening Platform](#)
  - [Target Identification](#)
  - [Development Platform](#)

---

**Note:** Includes past and present GHIT Fund Partners' logos. The awarded amount refers to the conditional investment figure agreed at the initiation of each project. GHIT invests using Japanese yen. US dollar amounts represent conversions from Japanese yen, solely for the reader’s convenience, at JPY 100 = USD 1.

---

**Legend:**
- **STAGE-GATE**
- **Current Status**
- **STAGE ACTIVITY**
- **MILESTONE**
- **PHASE 1**
- **PHASE 2**
- **PHASE 3**
- **PRECLINICAL**
- **CLINICAL**

---

**Project Scope vs Current Reporting Period Status**

<table>
<thead>
<tr>
<th>Activity</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preclinical Development</strong></td>
<td>completed</td>
</tr>
<tr>
<td><strong>Clinical Development</strong></td>
<td>completed</td>
</tr>
<tr>
<td><strong>Registration</strong></td>
<td>approved</td>
</tr>
<tr>
<td><strong>Supplemental Lic./PQ Plan</strong></td>
<td>granted</td>
</tr>
<tr>
<td><strong>Supp. Lic./PQ Dossiers</strong></td>
<td></td>
</tr>
<tr>
<td><strong>FPI</strong></td>
<td></td>
</tr>
<tr>
<td><strong>FPI</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LPI</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LPO</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

**Partners:**
- Tuberculosis
- Malaria
- Chagas disease
- Leishmaniasis
- Onchocerciasis
- Lymphatic filariasis
- Helminthiasis

---

**Tuberculosis** 150,000, **Malaria** 65,836, **Chagas disease** 1,517,220, **Leishmaniasis** 949,700, **Onchocerciasis** 119,000, **Lymphatic filariasis** 990,050, **Helminthiasis** 882,350.